Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Acenocoumarol in Antiphospholipid Syndrome
NCT02926170Phase 3Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Mar 2013
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in antiphospholipid syndrome (APS) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoints: Development of a new thrombotic event at 36 months and Incidence of major bleeding at 36 months. Started Mar 2013; status: completed.
02
Drugs
rivaroxaban
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT02926170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926170.